Inhibition of lung cancer cell proliferation mediated by human mesenchymal stem cells

Acta Biochimica et Biophysica Sinica

Volumn 43, Issue 2, 2011, Pages 143-148

  Li, Lin ^a   Tian, Hui ^a   Chen, Zhitao ^b   Yue, Weiming ^a   Li, Shuhai ^a   Li, Wenjun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Lung cancer; Mesenchymal stem cell; Proliferation; Vascular endothelial growth factor

Indexed keywords

CASPASE 3; VASCULOTROPIN A;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CELL SURVIVAL; COCULTURE; CULTURE MEDIUM; DOWN REGULATION; DRUG EFFECT; FEMALE; HUMAN; LUNG TUMOR; MESENCHYMAL STEM CELL; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; SECRETION; TUMOR CELL CULTURE; XENOGRAFT;

ANIMALS; APOPTOSIS; CASPASE 3; CELL SURVIVAL; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; FEMALE; HUMANS; LUNG NEOPLASMS; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ANIMALIA;

EID: 79551572124     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmq118     Document Type: Article

References (24)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD and Moorman MA, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284: 143-147.
2. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG and Ross J, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003, 425: 836-841.
3. Di NM, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P and Grisanti S, et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99: 3838-3843.
4. Le BK, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M and Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363: 1439-1441.
5. Wulf GG, Chapuy B and Trumper L. Mesenchymal stem cells from bone marrow. Phenotype, aspects of biology, and clinical perspectives. Med Klin (Munich) 2006, 101: 408-413.
6. Mathiasen AB, Haack-Sorensen M and Kastrup J. Mesenchymal stromal cells for cardiovascular repair: current status and future challenges. Future Cardiol 2009, 5: 605-617.
7. Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II and Nguyen AT, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006, 203: 1235-1247.
8. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC and Ye L, et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008, 18: 500-507.
9. Roorda BD, ter Elst A, Kamps WA and de Bont ES. Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol 2009, 69: 187-198.
10. Ramasamy R, Lam EF, Soeiro I, Tisato V, Bonnet D and Dazzi F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 2007, 21: 304-310.
11. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103: 4619-4621.
12. Kumar S and Lavin MF. The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ 1996, 3: 255-267.
13. Hanahan D and Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86: 353-364.
14. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407: 242-248.
15. Papetti M and Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002, 282: C947-C970.
16. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D and Yancopoulos GD, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284: 1994-1998.
17. Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A and Tonn JC, et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002, 109: 777-785.
18. Reck M and Crinò L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009, 63: 1-9.
19. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C and Li SF, et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 2008, 7: 245-251.
20. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J and Noël D, et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102: 3837-3844.
21. Zhu W, Xu W, Jiang R, Qian H, Chen M, Hu J and Cao W, et al. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp Mol Pathol 2006, 80: 267-274.
22. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN and Champlin RE, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004, 96: 1593-1603.
23. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B and Andreeff M, et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4: e4992.
24. Bunn PA, Jr, Shepherd FA, Sandler A, Chevalier TL, Belani CP, Kosmidis PA and Scagliotti GV, et al. Ongoing and future trials of biologic therapies in lung cancer. Lung Cancer 2003, 41: 175-186.